Last reviewed 2026-04-22 · How we verify

Luvox CR

Luvox CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron.

Luvox CR is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin availability in the brain by blocking its reuptake at the presynaptic neuron. Used for Obsessive-compulsive disorder (OCD), Social anxiety disorder, Depression.

At a glance

Mechanism of action

Fluvoxamine, the active ingredient in Luvox CR, selectively inhibits the reuptake of serotonin at the serotonin transporter (SERT), leading to increased serotonin concentration in the synaptic cleft. This enhanced serotonergic neurotransmission is thought to improve mood regulation and reduce anxiety and obsessive-compulsive symptoms. The extended-release formulation provides sustained drug levels throughout the day.

Approved indications

• Obsessive-compulsive disorder (OCD)
• Social anxiety disorder

Common side effects

• Nausea
• Headache
• Insomnia
• Somnolence
• Asthenia/fatigue
• Diarrhea
• Anorexia
• Sexual dysfunction

Key clinical trials

• COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) (PHASE3)
• Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms (PHASE3)
• Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
• Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
• Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2) (PHASE3)
• Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients (PHASE4)
• Fluvoxamine to Augment Olfactory Recovery For Long COVID-19 Parosmia (PHASE2)
• A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.